-
Accelerating Drug Discovery at the Intersection of Computer Science & Biotechnology.
-
CompBio Technology PlatformAt BioXplor we are building an integrated CompBio platform to accelerate discoveries and reduce failures in life science R&D. The integrated drug discovery platform works by generating obvious and non-obvious knowledge on a topic from structured and unstructured data using proprietary natural language processing, machine learning and bioinformatics algorithms. Our next stage is validating predictions in vitro via engineered disease models, patient samples and bio-activity screening for drug discovery. We have successfully applied the platform for indication expansion, drug repositioning, target ID, biomarker discovery, super responder ID and pathway discovery, with clients including top 5 pharma and biotech companies. BioXplor’s technology is available for licensing and we operate a CRO model, while our internal R&D is focused on building in silico and in vitro models for drug discovery in the area of metabolic disease.
-
BioXplor has built a unique biomedical knowledge-base consisting of billions of data points from public and private content including biomedical literature, clinical trials data, bioinformatics databases, biomedical ontologies, patient genetics, gene expression and phenotypic screening datasets. The platform can be integrated into pharma and biotech workflows for combined analysis and interpretation. Next, the team is generating in-house cell-based disease models to validate in silico genererated hypotheses. BioXplor has access to proprietary patient genetics and genomics databases via partnerships and in-house programs. We are building out a proprietary knowledgebase on metabolic disease, and interested to partner with organisations using or generating such data.Biomedical Knowledgebase
-
About us
BioXplor was founded in January 2017 and is backed by UC Berkeley Skydeck, Merck & European Innovation Council (Horizon 2020) accelerators, amongst other investment partners. The 10 person strong team has combined expertise in computer science and biomedical science applied to drug discovery, which are the core components of what we do, in equal measure. We are passionate about developing data-driven approaches to accelerate and improve Life Science R&D. Cofounders: Mark Rogers, MSc (Molecular Biotech) is CEO and has a over 15 years experience in emerging biotechnology, in industry and academia, including gene editing applications, membrane protein-protein screening, cell based gene therapy. He was previously Associate Director, Emerging Biotechnology Initiative (Europe) at Merck KgaA. Pavel Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a specialised CompBio background combining high performance computing, bioinformatics and software engineering. He previously worked on bioinformatics and machine learning research at Cranfield University. Anna O'Leary, BA (Economics & Finance) is COO, and brings management, finance and business operations expertise to the team. At Aramark she won an award for change management and team building, and worked at RBS Global Markets in the US in trading floor operations.
Contact
Partners
